611 related articles for article (PubMed ID: 31756363)
1. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
Vodenkova S; Buchler T; Cervena K; Veskrnova V; Vodicka P; Vymetalkova V
Pharmacol Ther; 2020 Feb; 206():107447. PubMed ID: 31756363
[TBL] [Abstract][Full Text] [Related]
2. GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA
An J; Seok H; Ha EM
J Microbiol; 2021 Feb; 59(2):202-216. PubMed ID: 33527319
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of colorectal cancer: history and new themes.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-3-S18-7. PubMed ID: 9420015
[TBL] [Abstract][Full Text] [Related]
4. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
5. Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells.
Paul S; Chatterjee S; Sinha S; Dash SR; Pradhan R; Das B; Goutam K; Kundu CN
Expert Opin Ther Targets; 2023; 27(10):999-1015. PubMed ID: 37787493
[TBL] [Abstract][Full Text] [Related]
6. Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer.
Wang T; Ning K; Sun X; Zhang C; Jin LF; Hua D
BMC Cancer; 2018 Feb; 18(1):207. PubMed ID: 29463225
[TBL] [Abstract][Full Text] [Related]
7. Role of genomic markers in colorectal cancer treatment.
Allen WL; Johnston PG
J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
[TBL] [Abstract][Full Text] [Related]
8. Where do we stand with 5-fluorouracil?
Schmoll HJ; Büchele T; Grothey A; Dempke W
Semin Oncol; 1999 Dec; 26(6):589-605. PubMed ID: 10606252
[TBL] [Abstract][Full Text] [Related]
9. Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer.
Song M; Yang J; Di M; Hong Y; Pan Q; Du Y; Xiang T; Liu J; Tang Y; Wang Q; Li Y; He J; Chen H; Zhao J; Weng D; Zhang Y; Xia JC
Theranostics; 2023; 13(5):1649-1668. PubMed ID: 37056569
[No Abstract] [Full Text] [Related]
10. MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.
Li PL; Zhang X; Wang LL; Du LT; Yang YM; Li J; Wang CX
Carcinogenesis; 2015 Dec; 36(12):1484-93. PubMed ID: 26442524
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
12. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
13. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
Kawakami K; Matsunoki A; Kaneko M; Saito K; Watanabe G; Minamoto T
Cancer Sci; 2011 Jan; 102(1):166-74. PubMed ID: 21087350
[TBL] [Abstract][Full Text] [Related]
14. The prodrugs of 5-fluorouracil.
Malet-Martino M; Jolimaitre P; Martino R
Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):267-310. PubMed ID: 12678747
[TBL] [Abstract][Full Text] [Related]
15. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
16. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Malet-Martino M; Martino R
Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
[TBL] [Abstract][Full Text] [Related]
17. Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells.
Lee KC; Lin CT; Chang SF; Chen CN; Liu JL; Huang WS
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29117108
[TBL] [Abstract][Full Text] [Related]
18. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Xie T; Geng J; Wang Y; Wang L; Huang M; Chen J; Zhang K; Xue L; Liu X; Mao X; Chen Y; Wang Q; Dai T; Ren L; Yu H; Wang R; Chen L; Chen C; Chu X
Oncotarget; 2017 Jan; 8(5):8574-8589. PubMed ID: 28051999
[TBL] [Abstract][Full Text] [Related]
20. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Oncologist; 1999; 4(6):478-87. PubMed ID: 10631692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
